Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis

References

• Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326:165–176. doi:10.1001/jama.2021.7683
   PubMedGoogle Scholar
• Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25–37. doi:10.1016/j.arcmed.2020.11.010
   PubMed Web of Science ®Google Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–2564. doi:10.1016/j.cell.2021.04.015
   PubMed Web of Science ®Google Scholar
• Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–115. doi:10.1016/j.cellsig.2018.06.005
   PubMed Web of Science ®Google Scholar
• Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295:G718–724. doi:10.1152/ajpgi.90232.2008
   PubMed Web of Science ®Google Scholar
• Avila DV, Barker DF, Zhang J, McClain CJ, Barve S, Gobejishvili L. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol. 2016;240:96–107. doi:10.1002/path.4760
   PubMed Web of Science ®Google Scholar
• Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99:7628–7633. doi:10.1073/pnas.122041599
   PubMed Web of Science ®Google Scholar
• Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005;175:1523–1531. doi:10.4049/jimmunol.175.3.1523
   PubMed Web of Science ®Google Scholar
• Gobejishvili L, Barve S, Breitkopf-Heinlein K, et al. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4. J Pharmacol Exp Ther. 2013;347:80–90. doi:10.1124/jpet.113.204933
   PubMed Web of Science ®Google Scholar
• Rodriguez WE, Wahlang B, Wang Y, et al. Phosphodiesterase 4 inhibition as a therapeutic target for alcoholic liver disease: from bedside to bench. Hepatology. 2019;70:1958–1971. doi:10.1002/hep.30761
   PubMed Web of Science ®Google Scholar
• Feng H, Chen J, Wang H, et al. Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice. Lab Invest. 2017;97:1008–1019. doi:10.1038/labinvest.2017.59
   PubMed Web of Science ®Google Scholar
• Essam RM, Ahmed LA, Abdelsalam RM, El-Khatib AS. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways. Life Sci. 2019;222:245–254. doi:10.1016/j.lfs.2019.03.014
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 1992;26:59–64. doi:10.1159/000118897
   PubMed Web of Science ®Google Scholar
• Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008;155:308–315. doi:10.1038/bjp.2008.307
   PubMed Web of Science ®Google Scholar
• Krause W, Kuhne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica. 1988;18:561–571. doi:10.3109/00498258809041693
   PubMed Web of Science ®Google Scholar
• Nelissen E, van Goethem NP, Bonassoli VT, et al. Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. Neurosci Lett. 2019;699:41–46. doi:10.1016/j.neulet.2019.01.026
   PubMed Web of Science ®Google Scholar
• Robichaud A, Savoie C, Stamatiou PB, et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol. 2002;135:113–118. doi:10.1038/sj.bjp.0704457
   PubMed Web of Science ®Google Scholar
• Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology. 2001;40:262–269. doi:10.1016/S0028-3908(00)00142-8
   PubMed Web of Science ®Google Scholar
• Robichaud A, Tattersall FD, Choudhury I, Rodger IW. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 1999;38:289–297. doi:10.1016/s0028-3908(98)00190-7
   PubMed Web of Science ®Google Scholar
• Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:1045–1052. doi:10.1172/JCI15506
   PubMed Web of Science ®Google Scholar
• Goga L, Pushpakumar SB, Perez-Abadia G, et al. A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues. J Surg Res. 2011;165:e51–57. doi:10.1016/j.jss.2010.09.033
   PubMed Web of Science ®Google Scholar
• Cai X, Li R. Concurrent profiling of polar metabolites and lipids in human plasma using HILIC-FTMS. Sci Rep. 2016;6:36490. doi:10.1038/srep36490
   PubMed Web of Science ®Google Scholar
• Thevis M, Krug O, Schanzer W. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing. Rapid Commun Mass Spectrom. 2013;27:993–1004. doi:10.1002/rcm.6539
   PubMedGoogle Scholar
• Gobejishvili L, Avila DV, Barker DF, et al. S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther. 2011;337:433–443. doi:10.1124/jpet.110.174268
   PubMed Web of Science ®Google Scholar
• Avila DV, Myers SA, Zhang J, et al. Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation. Neuropharmacology. 2017;125:376–385. doi:10.1016/j.neuropharm.2017.08.011
   PubMed Web of Science ®Google Scholar
• Elnagdy M, Barve S, McClain C, Gobejishvili L. cAMP Signaling in pathobiology of alcohol associated liver disease. Biomolecules. 2020;10:1433. doi:10.3390/biom10101433
   PubMed Web of Science ®Google Scholar
• Bryant CD, Zhang NN, Sokoloff G, et al. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet. 2008;22:315–331. doi:10.1080/01677060802357388
   PubMed Web of Science ®Google Scholar